natgillin/translations-raw huggingface dataset:
The need to ensure that women of child-bearing potential are using reliable contraception and that patients should inform their doctors of any possibility of pregnancy before a new prescription is issued.
da je treba zagotoviti, da ženske v rodni dobi uporabljajo zanesljivo kontracepcijo in da bolnice obvestijo svojega zdravnika o vsaki možnosti zanositve, preden dobijo nov recept;
The need to evaluate patients for both active and inactive tuberculosis prior to starting the treatment, including use of appropriate screening tests,
Potreba po ovrednotenju bolnikov za tako aktivno kot neaktivno tuberkulozo pred začetkom zdravljenja, vključno z uporabo ustreznih presejalnih testiranj
the need to exclude infection before starting immunosuppressant treatment the need for all patients to be entered into a long term surveillance programme
potrebo po izključitvi okužbe pred uvedbo imunosupresivnega zdravljenja; potrebo, da se vsi bolniki vključijo v dolgotrajni program spremljanja.
The need to explain to and ensure understanding of by patients/carers:
bolnikom/skrbnikom je treba razložiti in se prepričati, da razumejo naslednje:
The need to inform patients about the benefits and risk of TYSABRI and provide them with:
Zahtevo, da se bolnike obvesti o koristih in tveganjih zdravljenja z zdravilom TYSABRI in se jim izroči:
The need to inform patients about the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis, and that they should alert their physician if these symptoms occur.
obveznost informiranja bolnika o zgodnjih znakih preobčutljivostnih reakcij, ki vključujejo koprivnico, splošno urtikarijo, stiskanje v prsih, hropenje, hipotenzijo in anafilakso, in da morajo na te simptome opozoriti svojega zdravnika, če se pojavijo;
The need to inform patients about the potential risk of transaminases elevations, the risk of liver injury and interactions with potent CYP 1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin);
Bolnike je potrebno obvestiti o morebitnem tveganju za zvišanje aminotransferaz, tveganju za poškodbo jeter in medsebojnem delovanju z močnimi zaviralci CYP1A2 (npr. fluvoksamin in ciprofloksacin);
The need to inform patients about the potential risk of transaminases elevations,the risk of liver injury and interactions with potent CYP 1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin);
Bolnike je potrebno obvestiti o morebitnem tveganju za zvišanje aminotransferaz, tveganju za poškodbo jeter in medsebojnem delovanju z močnimi zaviralci CYP1A2 (npr. fluvoksamin in ciprofloksacin);
The need to inform patients on adverse events related to QT interval prolongation
Bolnike je treba obvestiti o neželenih učinkih, povezanih s podaljšanjem intervala QT.
The need to inform patients that TROBALT may cause a confusional state, hallucinations and psychotic disorders and the need to comply with dose titration to minimize these risks;
Bolnike je treba obvestiti, da se lahko pri uporabi zdravila TROBALT pojavijo stanje zmedenosti, halucinacije in psihotične motnje, zato naj se držijo titracije odmerka, da bi čim bolj zmanjšali ta tveganja.
The need to inform patients that TROBALT may cause or potentiate symptoms of urinary retention/urinary hesitation
Bolnike je treba obvestiti, da zdravilo TROBALT lahko povzroči ali potencira simptome retence urina/zastajanja curka urina.
The need to inform patients that TROBALT may cause pigment changes in ocular tissues, including the retina, and also in the skin, lips and/or nails, as well as a distinct form of macular abnormality with features of vitelliform maculopathy;
Bolnike je treba obvestiti, da lahko zdravilo TROBALT povzroča pigmentne spremembe v očesnih tkivih, vključno z mrežnico, pa tudi na koži, ustnicah in/ali nohtih, kot tudi posebno obliko nenormalnosti makule z značilnostmi viteliformne makulopatije.
The need to inform the National Competent Authority about any cases of PML
Zahtevo, da se nacionalni pristojni organ obvesti o vseh primerih PML
The need to inform the patient about the signs and symptoms associated with the treatment and when to seek attention from the health care provider.
potreba po informiranju bolnikov o znakih in simptomih, ki so povezani z zdravljenjem, ter o
The need to inform their doctor if they have had any liver problems in the past;
Potrebo po obveščanju svojega zdravnika o kakršnih koli težavah z jetri v preteklosti;
The need to inform their doctor of all other medications they are taking as special care should be taken if other drugs which can cause liver problems are taken at the same time;
Potrebo po obveščanju zdravnika o vseh drugih zdravilih, ki jih jemljejo, saj je treba biti še posebej previden, če se sočasno jemljejo zdravila, ki lahko povzročijo težave z jetri;
The need to instruct patients on proper techniques for self-administration when the patient is willing and capable to do so, and guidance for Health Care Professionals on how to report administration errors;
o potrebi, da bolnike poučijo o pravilnih tehnikah za samodajanje, kadar je bolnik voljan in sposoben za to, in smernice za zdravstvene delavce za poročanje o administrativnih napakah;
The need to instruct patients to report signs and symptoms of infections immediately to their prescriber during and for up to two months after treatment with GILENYA.
Bolnikom je treba naročiti, naj v času zdravljenja in do dva meseca po zaključku zdravljenja z zdravilom GILENYA svojega zdravnika takoj obvestijo, če opazijo kakršnekoli znake ali simptome okužbe.
The need to interrupt treatment if persistent and progressive increase in liver enzyme were noted.
potrebnost prekinitve zdravljenja, če pride do persistentnega in progresivnega zvišanja vrednosti jetrnih encimov;
the need to investigate as per usual clinical practice persistence of endometrial thickening following treatment discontinuation and return of menstruation to exclude other underlying conditions. recommendation of a periodic monitoring of the endometrium in case of repeated intermittent treatment.
informacija, da je treba skladno z običajno klinično prakso raziskati perzistenco odebelitve endometrija po prekinitvi zdravljenja in ponovnem pojavu menstruacije, da se izločijo druge obstoječe bolezni, priporočilo rednega spremljanja stanja endometrija pri ponavljajočem se intermitentnem zdravljenju.
The need to keep Erivedge capsules out of sight and reach of children
Potrebo po shranjevanju kapsul Erivedge nedosegljivo otrokom
The need to monitor and to contact the healthcare professionals if the following signs and symptoms occur after treatment:
Potreba po spremljanju in obveščanju zdravnika, če po zdravljenju pride do naslednjih znakov in simptomov:
The need to monitor regularly skin and to consider X-ray examinations of the bone as necessary.
potrebo po rednem spremljanju kože in rentgenskem slikanju kosti, kadar je to potrebno;
The need to monitor serum creatinine
potrebnost spremljanja koncentracije kreatinina v serumu,
The need to monitor serum ferritin monthly
potrebnost mesečnega spremljanja feritina v serumu;
the need to obtain the patient’s informed consent prior to treatment how to enter patients in it – including those not treated with Glybera
potreba po pridobivanju bolnikovega informiranega soglasja pred zdravljenjem; kako vključevati bolnike v register – vključno z bolniki, ki se ne zdravijo z zdravilom Glybera.
The need to perform liver function tests at the same frequency as at treatment initiation in all patients where the dosage is increased;
Pri vseh bolnikih je treba ob povečanju odmerka pregledovati delovanje jeter v enakih razmakih kot ob uvedbi zdravljenja;
The need to perform liver function tests in all patients before starting treatment and periodically thereafter around three, six (end of acute phase), twelve and twenty four weeks (end of maintenance phase), and thereafter when clinically indicated;
Pri vseh bolnikih je potrebno pregledovati delovanje jeter pred uvedbo zdravljenja in nato redno, po približno 3 tednih, 6 tednih (na koncu akutne faze), 12 tednih in 24 tednih (na koncu vzdrževalne faze) ter pozneje, ko je to klinično indicirano;
The need to provide comprehensive advice and counselling to patients
obveznost izčrpnega svetovanja in vodenja bolnika,
The need to provide comprehensive advice and counselling to patients.
bolnikom morajo zagotoviti izčrpna navodila in svetovanje;
The need to provide patients with the appropriate information booklet(s) and patient reminder card.
bolnikom morajo predati ustrezno informacijsko brošuro (brošure) in opozorilni kartonček za bolnika;
The need to provide patients with the educational material and explain the use of the patient alert card
Potrebo, da se bolnikom zagotovi izobraževalno gradivo in jim pojasniti, kako naj uporabljajo opozorilno izkaznico za bolnika
The need to provide patients with the patient reminder card.
Zdravnik mora bolniku izročiti opozorilno kartico za bolnika.
The need to provide the educational material to patients and request their informed consent to be enrolled into the registry prior to treatment
Potreba po posredovanju izobraževalnega gradiva bolnikom in potreba po pridobitvi prostovoljnega soglasja za vključevanje v register pred zdravljenjem
The need to re-treat cats which are likely to be re-infested, and the time interval between such treatments, should be based on an assessment by the responsible veterinarian.
Potrebo po ponovitvi odmerka zdravila pri mačkah, ki so podvržene ponovni okužbi ter časovni interval med odmerki naj oceni odgovoren veterinar.
The need to refer patients who become pregnant to a physician specialised or experienced in teratology and its diagnosis for evaluation and advice.
Bolnico, ki je zanosila, je treba za oceno in svetovanje napotiti k zdravniku, specializiranemu ali izkušenemu na področju teratologije in ustreznega svetovanja.
The need to refer the patient to a specialist physician
bolnika je potrebno napotiti k zdravniku specialistu
The need to report any symptoms of visual impairment immediately to the prescriber during and for up to two months after the end of treatment with GILENYA.
Pomembnost takojšnjega obveščanja lečečega zdravnika, če pride do simptomov okvare vida v času zdravljenja in še najmanj dva meseca po prekinitvi zdravljenja z zdravilom GILENYA.
The need to report immediately symptoms indicating low heart rate (such as dizziness, vertigo, nausea or palpitations) after the first dose of GILENYA.
Pomembnost takojšnjega obveščanja lečečega zdravnika v primeru simptomov, ki kažejo na znižanje srčne frekvence (kot so omotičnost, vrtoglavica, slabost ali palpitacije) po prvem odmerjanju zdravila GILENYA.
The need to screen donors using patient questionnaires and laboratory tests for hepatitis C, hepatitis B, HIV and syphilis
Potreba po presejanju darovalcev z uporabo vprašalnikov in laboratorijskih preskusov za hepatitis C, hepatitis B, HIV in sifilis.
The need to seek immediate medical attention especially in event of swallowing, speech and respiratory difficulties.
Potreba po takojšnji medicinski pomoči, zlasti v primeru težav s požiranjem, govorom ali dihanjem.
The need to stop treatment with FABLYN and investigate when unexplained uterine bleeding occurs.
Potreba po prekinitvi zdravljenja z zdravilom FABLYN in raziskavi vzrokov za pojav nepojasnjene krvavitve iz maternice.
The need to tell patients to report immediately to the treating healthcare professional if pregnancy is suspected in a female patient, or in a female partner of a male patient
Potrebo po obveščanju bolnikov, da morajo takoj poročati svojemu lečečemu zdravniku, če gre za sum na nosečnost pri bolnici ali če gre za sum na nosečnost pri partnerici bolnika
The need to tell patients to report immediately to the treating healthcare professional if pregnancy is suspected in a female patient, or in a female partner of a male patient
zahtevo po opozarjanju bolnikov, naj takoj obvestijo svojega lečečega zdravnika, če gre za sum na nosečnost pri bolnici ali pri partnerki moškega bolnika
The need to use condoms when having sex with a female partner
potrebo po uporabi kondoma pri spolnem odnosu z žensko partnerico
The needle
Igla
The needle cap of the syringe may contain dry rubber (latex), which should not be handled by persons sensitive to this substance.
Pokrovček igle pri injekcijski brizgi lahko vsebuje suho gumo (lateks), zato z njim ne smejo rokovati osebe s preobčutljivostjo na to snov.
The needle cap of the syringe may contain dry rubber (latex), which should not be handled by persons sensitive to this substance.
Zaporka na igli na brizgi lahko vsebuje suho gumo (lateks) in je ne smejo uporabljati osebe, ki so preobčutljive na to snov.
The needle cap of the syringe may contain dry rubber (latex).
Zaporka na igli na brizgi lahko vsebuje suho gumo (lateks).
The needle cap on the pre-filled syringe contains a derivative of latex and may cause severe allergic reactions experience a cough, fever and difficulty breathing.
Pokrovček igle na napolnjeni injekcijski brizgi vsebuje derivat lateksa in lahko povzroči hude alergijske reakcije. začnete kašljati, se vam zviša telesna temperatura in začnete težko dihati.
The needle cap on the pre-filled syringe contains a derivative of latex and may cause severe allergic reactions.
Pokrovček igle na napolnjeni injekcijski
The needle cover contains latex rubber.
Ščitnik igle vsebuje lateks gumo.
The needle cover contains latex rubber.
Ščitnik vsebuje lateks gumo.
The needle cover contains natural rubber latex.
Pokrovček igle vsebuje gumo iz naravnega lateksa.
The needle cover of the glass pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause allergic reactions.
Pokrovček igle na steklenem napolnjenem injekcijskem peresniku je izdelan iz suhe naravne gume (derivat lateksa), ki lahko povzroči alergijske reakcije.
The needle cover of the pre-filled pen contains dry natural rubber (a derivative of latex), which may cause allergic reactions.
Pokrovček igle na napolnjenem injekcijskem peresniku vsebuje suho naravno gumo (derivat lateksa), ki lahko povzroči alergijske reakcije.
The needle cover of the pre-filled pen contains dry natural rubber (a derivative of latex), which may cause allergic reactions.
Pokrovček igle pri napolnjenem injekcijskem peresniku vsebuje suho naravno gumo (derivat lateksa), ki lahko povzroča alergične reakcije.
The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex, see section 4.4).
Pokrovček igle napolnjenega injekcijskega peresnika je izdelan iz suhe naravne gume (derivat lateksa, glejte poglavje 4.4).
The needle cover of the pre-filled syringe contains dry natural rubber (a derivative of latex) which may cause an allergic reaction.
Pokrovček za iglo napolnjene injekcijske brizge vsebuje suho naravno gumo (derivat lateksa), ki lahko povzroči alergijsko reakcijo.
The needle cover of the pre-filled syringe contains latex (dry natural rubber) that may cause hypersensitivity reactions when handled by or when Enbrel is administered to persons with known or possible latex sensitivity.
Pokrovček igle napolnjene injekcijske brizge vsebuje lateks (posušen naravni kavčuk), ki lahko povzroči preobčutljivostne reakcije, če z zdravilom Enbrel ravna oseba z znano ali možno preobčutljivostjo na lateks ali če ga damo taki osebi.
The needle cover of the pre-filled syringe is made from dry natural rubber (a derivative of latex, see section 4.4).
Pokrovček igle napolnjene injekcijske brizge je izdelan iz suhe naravne gume (derivat lateksa, glejte poglavje 4.4).
The needle cover of this medicine contains natural rubber latex which may cause allergic reactions.
Pokrovček igle tega zdravila vsebuje gumo iz naravnega lateksa, ki lahko povzroči alergijske reakcije.
The needle cover on the pre-filled pen is manufactured from dry natural rubber containing latex, and may cause allergic reactions in individuals sensitive to latex.
Ščitnik igle na napolnjenem injekcijskem peresniku ali napolnjeni injekcijski brizgi je izdelan iz suhe naravne gume, ki vsebuje lateks in lahko povzroča alergijske reakcije pri posameznikih, ki so občutljivi za lateks.
The needle cover should not be removed until you are ready to inject the dose
Pokrovčka ne snemajte z igle, dokler niste pripravljeni za injiciranje odmerka.
The needle cover should not be removed while allowing the pre- filled pen to reach room temperature.
Med čakanjem, da se napolnjeni injekcijski peresnik segreje na sobno temperaturo, pokrovčka igle ne smete odstraniti.
The needle cover should not be removed while allowing the pre- filled syringe to reach room temperature.
Med čakanjem, da se napolnjena injekcijska brizga segreje na sobno temperaturo, pokrovčka igle ne smete odstraniti.
The needle cover should not be removed while allowing the pre-filled pen to reach room temperature.
Med čakanjem, da se napolnjen injekcijski peresnik segreje na sobno temperaturo, pokrovčka igle ne smemo odstraniti.
The needle cover should not be removed while allowing the pre-filled syringe to reach room temperature.
Med čakanjem, da se napolnjena injekcijska brizga segreje na sobno temperaturo, pokrovčka igle ne smete odstraniti.
The needle cover will extend covering the needle completely.
Varovalo igle izskoči in povsem prekrije iglo.
The needle cover will extend to cover the needle (See Figure M).
Varovalo igle bo izskočilo in pokrilo iglo (glejte sliko M).
The needle for intramuscular injection is provided.
Igla za intramuskularno injiciranje (modra) je priložena.
The needle has been placed in a plastic container to keep it sterile.
Igla se nahaja v plastični embalaži, da ostane sterilna.
The needle is attached by twisting in clockwise direction, until the needle fits securely on the syringe.
Iglo pritrdite tako, da jo zavrtite v smeri urinega kazalca, dokler se igla zanesljivo ne prilega na injekcijsko brizgo.
The needle is covered by the needle cover and will not be visible.
Iglo pokriva varovalo igle, zato ni vidna.
The needle may be clogged, bent, or incorrectly attached.
Igla je morda zamašena, zvita ali nepravilno pritrjena.
The needle may then enter at an angle and bend, break or prevent proper removal of the vial contents.
V takšnem primeru lahko igla vstopi pod kotom in se zvije, zlomi ali prepreči pravilno odstranitev vsebine viale.
The needle must go all the way in.
Iglo zabodite do konca.
The needle safety device will not activate unless the entire dose is given.
Varnostni mehanizem igle se ne bo sprožil, če ni bil apliciran celoten odmerek.
The needle safety guard covers the needle after injection to prevent needle stick injury.
Varnostna zaščita za iglo po injiciranju takoj prekrije iglo in s tem ščiti pred morebitnimi poškodbami zaradi vboda.
The needle safety guard prevents needle stick injuries after use, so no special precautions for disposal are required.
Varnostna zaščita za iglo preprečuje poškodbe zaradi vboda z iglo po uporabi, tako da za odstranjevanje niso potrebni nobeni posebni previdnostni ukrepi.
The needle safety guard prevents needle stick injuries after use, so no special precautions for disposal are required.
Varnostni pripomoček preprečuje poškodbe zaradi vboda z iglo po uporabi, tako da za odstranjevanje niso potrebni nobeni previdnostni ukrepi.
The needle shield of the pre-filled syringe may contain dry natural latex rubber that has the potential to cause allergic reactions in latex sensitive individuals.
Ščitnik igle na napolnjeni injekcijski brizgi vsebuje suho naravno gumo iz lateksa, ki lahko osebam, občutljivim na lateks, povzroči alergijsko reakcijo.
The needle shield will retract completely when you insert the needle into the skin (see picture 10).
Zaščita igle se bo povsem umaknila, ko boste iglo vstavili v kožo (glejte sliko 10).
The needle should be carefully attached straight onto the pen.
Iglo je potrebno natančno namestiti naravnost na injekcijski peresnik.
The needle should be carefully attached straight onto the pen.
Iglo natančno namestite naravnost na injekcijski peresnik.
The needle should be inserted into the skin
Iglo je treba zabosti v kožo.
The needle should be inserted into the skin.
Iglo mora bolnik zabosti v kožo.
The needle should be pushed into the extremity of the syringe and rotated a quarter of a turn (90) to secure the connection.
Iglo morate potisniti na konico brizge in jo obrniti za četrt obrata (90°), da je pravilno nameščena.
The needle should be pushed on until you feel/hear a “click” rather than twisted on.
Iglo je treba potiskati, dokler ne začutite ali zaslišite "klik" namesto, da jo sukate.
The needle should be removed after each injection and discarded.
Po vsakem injiciranju je treba iglo odstraniti in zavreči.
The needle to be used for administration of TREVICTA into the gluteal muscle is the thin wall
Za injiciranje zdravila TREVICTA v glutealno mišico je treba uporabiti iglo s tanko steno, dolžine
The needle used for withdrawal must be replaced by a needle suitable for intramuscular injection.
Pred aplikacijo morate iglo, ki ste jo uporabili pri izvleku cepiva, zamenjati z iglo, primerno za intramuskularno aplikacijo.
The needle will automatically move back into the empty pen.
Injekcijska igla se bo avtomatično pomaknila nazaj v prazen peresnik.
The needle will automatically retract with an audible click.
Igla se bo s slišnim klikom samodejno povrnila v prvotno lego.
The needle will insert with an audible click, after which you will hear the sound of the motor running.
Injekcijska igla se vstavi s slišnim klikom, nato pa boste slišali zvok delujočega motorja.
The needle will remain in the long part of the package.
Igla bo ostala v daljšem delu embalaže.
The needle will withdraw automatically into the syringe where it will be locked permanently.
Igla se bo samodejno umaknila v injekcijsko brizgo in bo ostala v njej zaprta.
the needle-shield may not have locked.
je možno, da se ščitnik za iglo ni zaklenil.
The NeoRecormon pre-filled syringe is ready for use.
NeoRecormon napolnjena injekcijska brizga je pripravljena za uporabo.
The Nespo pre-filled pen should NEVER be reused.
Napolnjenega injekcijske peresnika Nespo ne smete NIKOLI ponovno uporabiti.
The net effect of lumacaftor/ivacaftor therapy is expected to be strong CYP3A induction.
Pričakovati je, da bo neto učinek zdravljenja z lumakaftorjem/ivakaftorjem močno spodbujanje CYP3A.
The net effect of these changes after seroconversion was an increase in exposure of 2- to 3-fold based on AUC and Cmax.
Neto učinek teh sprememb po serokonverziji je bil 2 do 3 krat večji po izpostavljenosti glede na AUC in Cmax.
The net result is the inhibition of lymphocyte activation, which results in immunosuppression.
Končni rezultat je zaviranje aktivacije limfocitov, ki vodi do zavore imunske odzivnosti.
The Netherlands
2031GA Haarlem Nizozemska
The Netherlands
5831 AN Boxmeer, Nizozemska
The NETHERLANDS
5831AN NIZOZEMSKA
The Netherlands
Genzyme Ltd
The Netherlands
Via San Martino 12
The Netherlands Tel.: +31 485 587600
Tel: +31 485 587600
The Netherlands The Netherlands
2031 GA Haarlem Nizozemska
The Netherlands.
Nizozemska
The neutralising antibody was not confirmed upon repeat testing 18 days later and was negative at subsequent visits.
Nevtralizirajoče protitelo ni bilo potrjeno pri ponovnem testiranju 18 dni pozneje in je bilo negativno pri sledečih obiskih.
The nevirapine AUC0-24,ss and Cmin,ss measured after 19 days of fasted dosing of Viramune 400 mg prolonged-release tablets once daily were approximately 80 % and 90 %, respectively, of the AUC0-24,ss and Cmin,ss measured when patients were dosed with Viramune 200 mg immediate-release tablets twice daily.
Nevirapinovi AUC0-24,ss in Cmin,ss, izmerjeni po 19 dneh jemanja odmerkov po 400 mg zdravila Viramune s podaljšanim sproščanjem na tešče, enkrat na dan, sta bili 80 % in 90 % AUC0-24,ss in Cmin,ss, izmerjenih po jemanju odmerkov zdravila Viramune 200 mg tablete s takojšnjim sproščanjem, dvakrat na dan.